Vericel Corp Ord (VCEL)
Return on total capital
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -3,685 | -11,080 | -13,735 | -16,717 | -15,613 | -18,257 | -16,736 | -11,506 | -7,578 | 613 | 9,163 | 4,608 | 3,050 | -141 | -664 | -12,596 | -11,251 | -14,466 | -18,899 | -2,945 |
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 225,952 | 204,380 | 198,928 | 193,978 | 192,272 | 177,837 | 174,816 | 172,485 | 170,462 | 156,780 | 151,092 | 140,209 | 134,260 | 114,630 | 107,596 | 110,452 | 111,091 | 96,990 | 88,542 | 103,055 |
Return on total capital | -1.63% | -5.42% | -6.90% | -8.62% | -8.12% | -10.27% | -9.57% | -6.67% | -4.45% | 0.39% | 6.06% | 3.29% | 2.27% | -0.12% | -0.62% | -11.40% | -10.13% | -14.91% | -21.34% | -2.86% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-3,685K ÷ ($—K + $225,952K)
= -1.63%
Vericel Corp's return on total capital has fluctuated over the past eight quarters, with negative figures recorded in each quarter. The return on total capital ranged from -2.86% to -10.69% during this period. The consistent negative trend indicates that the company is not generating sufficient returns from its total invested capital. Vericel Corp may need to address underlying inefficiencies or improve its operational performance to enhance its return on total capital in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Return on total capital
Vericel Corp Ord
VCEL
-1.63%
Amgen Inc
AMGN
11.38%
Bio-Techne Corp
TECH
9.82%
Biogen Inc
BIIB
7.15%
Gilead Sciences Inc
GILD
17.07%
Halozyme Therapeutics Inc
HALO
23.19%
Krystal Biotech Inc
KRYS
-8.46%
Moderna Inc
MRNA
-30.60%
Neurocrine Biosciences Inc
NBIX
15.09%
Regenxbio Inc
RGNX
-86.01%
Repligen Corporation
RGEN
2.66%